[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY25950A1 - Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea - Google Patents

Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Info

Publication number
UY25950A1
UY25950A1 UY25950A UY25950A UY25950A1 UY 25950 A1 UY25950 A1 UY 25950A1 UY 25950 A UY25950 A UY 25950A UY 25950 A UY25950 A UY 25950A UY 25950 A1 UY25950 A1 UY 25950A1
Authority
UY
Uruguay
Prior art keywords
same
treatment
prevention
resorption
oral
Prior art date
Application number
UY25950A
Other languages
English (en)
Inventor
Anastasia G Daifotis
Arthur C Santora Ii
A John Yates
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of UY25950A1 publication Critical patent/UY25950A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)

Abstract

METODO PARA EL TRATAMIENTO DE LA RESORCION OSEA ANORMAL EN UN MAMIFERO QUE REQUIERA DICHO TRATAMIENTO, MINIMIZANDO LA PRESENTACION DE EFECTOS GASTROINTESTINALES ADVERSOS, EL REFERIDO METODO COMPRENDE LA ADMINISTRACION ORAL EN DICHO MAMIFERO DE UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DEL BISFOSFONATO COMO UNIDAD DE DOSIFICACION, ACORDE CON UN ESQUEMA CONTINUO CON INTERVALOS ENTRE DOSIS QUE SE SELECCIONAN DEL GRUPO QUE CONSISTE EN UNA DOSIFICACION SEMANAL, DOS DOSIFICACIONES SEMANALES, UNA DOSIFICACION BISEMANAL Y DOS DOSIFICACIONES MENSUALES. ESTE ESQUEMA CONTINUO SE MANTIENE HASTA QUE SE LOGRA EL EFECTO TERAPEUTICO DESEADO EN DICHO MAMIFERO. EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UN METODO ORAL PARA LA PREVENCION DE LA RESORCION OSEA ANORMAL EN UN MAMIFERO EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UN METODO ORAL PARA LA PREVENCION O EL TRATAMIENTO DE LA RESORCION OSEA ANORMAL EN UN SER HUMANO. EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UN METODO ORAL PARA LA PREVENCION O EL TRATAMIENTO DE LA OSTEOPOROSIS EN UN MAMIFERO; A UN METODO ORAL PARA LA PREVENCION O EL TRATAMIENTO DE LA RESORCION OSEA ANORMAL EN UN SER HUMANO QUE REQUIERA DICHO TRATAMIENTO, COMPRENDIENDO LA ADMINISTRACION A DICHO SER HUMANO DE ENTRE APROXIMADAMENTE 8,75 MG Y APROXIMADAMENTE 140 MG. EN BASE A ACIDO ALENDRONICO ACTIVO, DE UN BISFOSFONATO SELECCIONADO DE UN GRUPO CONSISTENTE EN ALENDRONATO, SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO Y MEZCLAS DE LOS MISMOS. EN OTRAS REALIZACIONES DE LA INVENCION, LA MISMA SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ENTRE APROXIMADAMENTE L40 MG. EN BASE A ACIDO ALENDRONICO ACTIVO, DE UN BISFOSFONATO SELECCIONADO DE UN GRUPO CONSISTENTE EN ALENDRONATO, SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO Y MEZCLAS DE LOS MISMOS. TODOS LOS PORCENTAJES Y LAS RELACIONES UTILIZADAS EN EL PRESENTE SE REFIEREN A PESO EXCEPTO EN LOS CASOS EN QUE SE INDIQUE OTRA COSA. ESTA INVENCION PUEDE COMPRENDER LOS INGREDIENTES, COMPONENTES Y METODOS ESENCIALES Y OPCIONALES AQUÍ DESCRITOS, PUEDE CONSISTIR EN LOS MISMOS O PUEDE CONSISTIR ESENCIALMENTE EN LOS MISMOS
UY25950A 1997-07-22 2000-01-17 Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea UY25950A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
UY25950A1 true UY25950A1 (es) 2000-09-29

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25950A UY25950A1 (es) 1997-07-22 2000-01-17 Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Country Status (31)

Country Link
EP (5) EP1175903A3 (es)
JP (2) JP3479780B2 (es)
KR (3) KR100391732B1 (es)
CN (3) CN1166365C (es)
AT (2) ATE209037T1 (es)
AU (1) AU8493698A (es)
BG (1) BG66282B1 (es)
BR (1) BR9810779A (es)
CA (1) CA2294595C (es)
CY (2) CY1107535T1 (es)
DE (6) DE69803291T2 (es)
DK (2) DK1175904T3 (es)
EA (1) EA004544B2 (es)
EE (1) EE05603B1 (es)
ES (3) ES2164447T3 (es)
HK (4) HK1042230A1 (es)
ID (1) ID24096A (es)
IL (1) IL133535A0 (es)
IS (3) IS5315A (es)
LU (2) LU91222I2 (es)
NL (2) NL300223I1 (es)
NO (1) NO20000323L (es)
NZ (1) NZ501807A (es)
PL (1) PL195272B1 (es)
PT (2) PT1175904E (es)
SG (2) SG109478A1 (es)
SI (1) SI0998292T1 (es)
SK (1) SK932000A3 (es)
TR (1) TR200000145T2 (es)
UY (1) UY25950A1 (es)
WO (1) WO1999004773A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263566T1 (de) 1998-12-25 2004-04-15 Yamanouchi Pharma Co Ltd Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
WO2000071104A2 (en) * 1999-05-21 2000-11-30 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
DK1591122T3 (da) * 2000-06-20 2013-02-25 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
WO2001097788A2 (en) 2000-06-20 2001-12-27 Novartis Ag Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
EP1506041B1 (en) 2002-05-10 2007-10-24 F. Hoffmann-La Roche Ag Ibandronic acid for the treatment and prevention of osteoporosis
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MXPA06003063A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato.
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
AU2006290519B2 (en) * 2005-09-16 2012-10-18 Selamine Ltd Bisphosphonate formulation
CN103140220A (zh) * 2010-12-06 2013-06-05 给药技术公司 具有快速溶解特性的稳定的泡腾双磷酸盐制剂
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
DE69231313T2 (de) * 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DE69316013T2 (de) * 1992-06-30 1998-07-09 Procter & Gamble Pharma Verwendung von phosphinate zur behandlung der osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0831843A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
TR200000145T2 (tr) 2000-05-22
EP1175904A3 (en) 2002-12-18
DE122007000063I1 (de) 2007-12-20
NL300223I1 (nl) 2006-04-03
DE69837450T2 (de) 2007-08-23
BR9810779A (pt) 2000-07-25
EP1175904B8 (en) 2007-05-09
PL338635A1 (en) 2000-11-06
ES2164447T3 (es) 2002-02-16
PT998292E (pt) 2002-04-29
NL300292I1 (nl) 2007-11-01
CN1166365C (zh) 2004-09-15
WO1999004773A9 (en) 1999-10-28
PT1175904E (pt) 2007-04-30
IS7230A (is) 2004-04-21
IS5315A (is) 1999-12-21
DK0998292T3 (da) 2002-05-13
CN1265035A (zh) 2000-08-30
ES2269014T1 (es) 2007-04-01
EA200000151A1 (ru) 2000-10-30
DE69803291T2 (de) 2002-08-08
SG109478A1 (en) 2005-03-30
KR20010022110A (ko) 2001-03-15
KR20030097611A (ko) 2003-12-31
DE122006000009I1 (de) 2006-06-14
WO1999004773A2 (en) 1999-02-04
CA2294595C (en) 2001-08-21
EA004544B2 (ru) 2006-12-29
DE69837450D1 (de) 2007-05-10
WO1999004773A3 (en) 1999-04-15
SI0998292T1 (en) 2002-04-30
LU91222I2 (fr) 2006-04-18
HK1040494A1 (en) 2002-06-14
IL133535A0 (en) 2001-04-30
JP2005068010A (ja) 2005-03-17
DE01201911T1 (de) 2007-10-18
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
HK1024166A1 (en) 2000-10-05
EA004544B1 (ru) 2004-06-24
IS7231A (is) 2004-04-21
BG66282B1 (bg) 2013-01-31
SK932000A3 (en) 2000-09-12
DK1175904T3 (da) 2007-05-07
EE05603B1 (et) 2012-12-17
ATE209037T1 (de) 2001-12-15
EP1132088A2 (en) 2001-09-12
KR20030097610A (ko) 2003-12-31
EP1151752A2 (en) 2001-11-07
HK1040495A1 (en) 2002-06-14
CN1602880A (zh) 2005-04-06
EP0998292B1 (en) 2001-11-21
LU91364I2 (fr) 2007-11-12
ID24096A (id) 2000-07-06
KR100391732B1 (ko) 2003-07-16
BG104093A (en) 2000-10-31
JP2002502433A (ja) 2002-01-22
EP1175903A3 (en) 2002-12-18
HK1042232A1 (en) 2002-08-09
DE01201913T1 (de) 2007-02-08
ES2253136T1 (es) 2006-06-01
JP3479780B2 (ja) 2003-12-15
ATE357921T1 (de) 2007-04-15
EP1175903A2 (en) 2002-01-30
HK1042230A1 (en) 2002-08-09
CN1602879A (zh) 2005-04-06
PL195272B1 (pl) 2007-08-31
NZ501807A (en) 2003-02-28
EP0998292A2 (en) 2000-05-10
ES2269014T3 (es) 2007-05-01
NO20000323L (no) 2000-03-20
CA2294595A1 (en) 1999-02-04
EP1132088A3 (en) 2002-04-24
EP1175904B1 (en) 2007-03-28
AU8493698A (en) 1999-02-16
CN1299689C (zh) 2007-02-14
CY2007022I1 (el) 2012-01-25
EP1151752A3 (en) 2002-12-18
EP1175904A2 (en) 2002-01-30
EE200000040A (et) 2000-10-16
CY1107535T1 (el) 2012-01-25
CY2007022I2 (el) 2012-01-25
DE69803291D1 (de) 2002-02-21

Similar Documents

Publication Publication Date Title
UY25950A1 (es) Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea
US5853759A (en) Effervescent alendronate formulation
CA2254060C (en) Effervescent bisphosphonate formulation
ES2247123T7 (es) Método para administrar bisfosfonatos
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
YU31795A (sh) Oralne tečne formulacije alendronata
JPH08505142A (ja) 骨損失を治療及び予防するためのビスホスホネート/エストロゲン療法
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
DK0833643T3 (da) Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
AR037560A1 (es) Formulacion de altas dosis de ibandronato
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
MX9303243A (es) Compuestos de fosfonato novedosos que contienen nitrogeno cuaternario, composiciones farmaceuticas y metodos para tratar el metabolismo anormal del calcio y el fosfato, y metodos para tratar y prevenir calculos dentales y placa dental.
McClung Bisphosphonates
ES2060708T3 (es) Sistema terapeutico de liberacion retardada para formulaciones farmaceuticas liquidas.
AR013994A1 (es) Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
ES2215856T3 (es) Solucion de sal monosodica tetrahidrato de n-(o-(p-pivaloiloxibenceno-sulfonilamino)benzoil)glicina y medicamento que contiene esta solucion.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
ES2139013T3 (es) Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar el metabolismo anormal del calcio y fosfato.
US20060034921A1 (en) Effervescent bisphosphonate formulation
US20040137058A1 (en) Effervescent bisphosphonate formulation
US20070087052A1 (en) Effervescent bisphosphonate formulation
AR013500A1 (es) Uso de acido alendronico o una sal farmaceuticamente aceptable del mismo o una mezcal de los mismos para la manufactura de un medicamento
Moradi et al. Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041115